These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 2428660)
1. [Effects of epsilon-aminocaproic acid, amben and kontrikal on fibrinolysis due to tissue-type plasminogen activator from the pig heart]. Shimonaeva EE; Andreenko GV; Alieva NI Farmakol Toksikol; 1986; 49(4):35-8. PubMed ID: 2428660 [TBL] [Abstract][Full Text] [Related]
2. [Effect of synthetic and natural inhibitors on the activity of tissue activator from the swine heart in vitro]. Andreenko GV; Shimonaeva EE; Alieva NI Vopr Med Khim; 1986; 32(4):45-7. PubMed ID: 2429443 [TBL] [Abstract][Full Text] [Related]
3. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis. Thorsen S; Astrup T Thromb Diath Haemorrh; 1974 Dec; 32(2-3):306-24. PubMed ID: 4281113 [No Abstract] [Full Text] [Related]
4. Measurement of fibrinolytic activity after epsilon-aminocaproic acid administration in rats (Rattus norvegicus). Gogjian MA; Barry KJ; Stein BM Lab Anim Sci; 1981 Dec; 31(6):710-1. PubMed ID: 7343767 [TBL] [Abstract][Full Text] [Related]
5. Epsilon-aminocaproic acid inhibition of fibrinolysis in vitro: should the 'therapeutic' concentration be reconsidered? Nielsen VG; Cankovic L; Steenwyk BL Blood Coagul Fibrinolysis; 2007 Jan; 18(1):35-9. PubMed ID: 17179824 [TBL] [Abstract][Full Text] [Related]
6. Reversible and irreversible alterations of human plasminogen indicated by changes in susceptibility to plasminogen activators and in response to epsilon-aminocaproic acid. Thorsen S; Kok P; Astrup T Thromb Diath Haemorrh; 1974 Dec; 32(2-3):325-40. PubMed ID: 4450189 [No Abstract] [Full Text] [Related]
7. Synergistic antifibrinolytic action of the potato protease inhibitor and epsilon-aminocaproic acid. Worowski K Acta Biol Acad Sci Hung; 1976; 27(2-3):125-8. PubMed ID: 140568 [TBL] [Abstract][Full Text] [Related]
8. [Study of the effect of a dexamethasone-containing antirheumatic on the hypothalomus-adenohypophysis-adrenocortical system]. Jaeger H; Russmann D; Schlegel E; Tzonev I Arzneimittelforschung; 1982; 32(11):1489-96. PubMed ID: 6295416 [TBL] [Abstract][Full Text] [Related]
9. [Thrombolytic properties of the heparin-tissue plasminogen activator complex and its effect on the fibrinolytic and coagulating systems of the blood in animals]. Shimonaeva EE; Andreenko GV Vopr Med Khim; 1988; 34(1):59-62. PubMed ID: 3130724 [TBL] [Abstract][Full Text] [Related]
10. Action of epsilon-aminocaproic acid and of parotid inhibitor on the fibrinolysis activation due to nicotinic acid derivatives and to heparin-like substances. Gibelli A; Turazza G; Giarola P; De Nicola P Farmaco Sci; 1966 Apr; 21(4):301-9. PubMed ID: 4160699 [No Abstract] [Full Text] [Related]
11. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids. Thorsen S Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205 [No Abstract] [Full Text] [Related]
12. [Comparative effectiveness of epsilon-aminocaproic acid and contrical in preventing complement activation on immune complexes]. Tsibul'kin AP; Raĭzman SM Farmakol Toksikol; 1981; 44(3):316-9. PubMed ID: 6169545 [TBL] [Abstract][Full Text] [Related]
13. Comparison of recombinant plasminogen activator inhibitor-1 and epsilon amino caproic acid in a hemorrhagic rabbit model. Racanelli AL; Diemer MJ; Dobies AC; Dubin JR; Reilly TM Thromb Haemost; 1992 Jun; 67(6):692-6. PubMed ID: 1509411 [TBL] [Abstract][Full Text] [Related]
14. Cutaneous vascular fibrinolytic activity in the local Shwartzman reaction. Bergstein JM Am J Pathol; 1977 Sep; 88(3):655-62. PubMed ID: 407799 [TBL] [Abstract][Full Text] [Related]
15. The effective concentration of epsilon-aminocaproic Acid for inhibition of fibrinolysis in neonatal plasma in vitro. Yurka HG; Wissler RN; Zanghi CN; Liu X; Tu X; Eaton MP; Anesth Analg; 2010 Jul; 111(1):180-4. PubMed ID: 20519417 [TBL] [Abstract][Full Text] [Related]
17. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of fibrinolysis in rabbits exposed to low and moderate levels of carbon monoxide inhibited by epsilon amino caproic acid. Kalmaz EV; Canter LW; Coleman RL; Hampton JW Thromb Haemost; 1978 Feb; 39(1):109-21. PubMed ID: 580486 [TBL] [Abstract][Full Text] [Related]
19. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis. van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459 [TBL] [Abstract][Full Text] [Related]
20. The effect of dexamethasone on tissue fibrinolytic system in male and female rats. Tsantarliotou M; Taitzoglou I; Kokolis N In Vivo; 1999; 13(2):119-24. PubMed ID: 10363166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]